Prime Medicine, Inc.PRMENASDAQ
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank17
3Y CAGR-46.8%
5Y CAGR-56.6%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
-46.8%/yr
Annual compound
5Y CAGR
-56.6%/yr
Recent acceleration
Percentile
P17
Within normal range
vs 5Y Ago
0x
Contraction
Streak
2 yr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| 2025 | 3.44% |
| 2024 | 4.99% |
| 2023 | 70.54% |
| 2022 | 22.93% |
| 2021 | 2267.45% |
| 2020 | 223.91% |
| 2019 | 0.00% |